SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Metcalf who wrote (448)5/20/1999 9:20:00 AM
From: ouija  Read Replies (1) of 717
 
Wrong on patent protection. DUSA has an exclusive use patent on ALA covering the US, Japan, and elsewhere. It does not cover Europe. Any use for treatment of any type is covered by the patent.

ALA is aimed at multiple billion dollar markets. Approvable letter due from the FDA by July 1, panel scheduled for June 3, 90% efficacy rate for AK but off label much larger.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News